Darvadstrocel Misses Primary Endpoint in Complex Perianal Crohn’s Disease : CGH | Jun 2026

Introduction:

Complex perianal fistulas represent one of the most debilitating manifestations of Crohn’s disease, often causing chronic pain, drainage, recurrent infections, and substantial impairment in quality of life. Despite advances in biologic therapy, fistula healing remains difficult to achieve and sustain. Darvadstrocel, an allogeneic adipose-derived mesenchymal stem cell therapy, generated considerable enthusiasm following the positive ADMIRE-CD trial, which demonstrated improved fistula healing in selected patients with refractory disease.

Problem Statement:

Although earlier studies supported the efficacy of darvadstrocel, its performance in a broader international population and contemporary treatment setting remained uncertain. Confirmation of benefit in a larger phase 3 trial was necessary before establishing its role in routine management of complex perianal Crohn’s disease.

Summary:

The ADMIRE CD II trial evaluated the efficacy and safety of darvadstrocel in patients with complex perianal Crohn’s disease across Europe, Israel, and North America. All participants underwent standardized surgical preparation, including fistula curettage and closure of the internal opening, before receiving either darvadstrocel or placebo. Contrary to expectations generated by the earlier ADMIRE-CD study, darvadstrocel did not demonstrate superiority over placebo for the primary endpoint of combined remission at 24 weeks. Clinical remission rates and time to remission were also comparable between the treatment groups, indicating no meaningful therapeutic advantage. Importantly, the study confirmed a favorable safety profile, with adverse events occurring at similar rates in both groups and no new safety concerns identified. These findings represent a significant setback for stem cell-based therapy in complex perianal Crohn’s disease and highlight the challenges of translating promising early results into consistent benefits across broader patient populations. While darvadstrocel remains biologically attractive and well tolerated, the negative results of ADMIRE CD II raise important questions regarding patient selection, treatment timing, fistula characteristics, and trial design. Future research will be needed to identify subgroups most likely to benefit and to refine regenerative approaches for fistula healing in Crohn’s disease.